Skip to main content

Caries, Dental

1
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
IodinePhase 31 trial
Active Trials
NCT03062605Completed48Est. Feb 2012
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
2% Calcium Hypophosphite ToothpasteN/A1 trial
Active Trials
NCT07068204Recruiting164Est. Jan 2028
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
Data collectionN/A1 trial
Active Trials
NCT02958891Unknown700Est. Dec 2017
Solventum
SolventumMN - St. Paul
1 program
Vitrebond™ Pulp Protect Liner/BaseN/A1 trial
Active Trials
NCT07261137Not Yet Recruiting160Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Angeles TherapeuticsIodine
Integrated Biosciences2% Calcium Hypophosphite Toothpaste
SolventumVitrebond™ Pulp Protect Liner/Base
Jerusalem PharmaceuticalsData collection

Clinical Trials (4)

Total enrollment: 1,072 patients across 4 trials

NCT03062605Angeles TherapeuticsIodine

Reducing Bacteria That Cause Tooth Decay

Start: May 2011Est. completion: Feb 201248 patients
Phase 3Completed
NCT07068204Integrated Biosciences2% Calcium Hypophosphite Toothpaste

Comparative Study of Caries-Preventive Effects: 2% Calcium Hypophosphite Toothpaste vs. Sodium Fluoride Toothpaste (1450ppm F)

Start: Jan 2026Est. completion: Jan 2028164 patients
N/ARecruiting
NCT07261137SolventumVitrebond™ Pulp Protect Liner/Base

Efficacy of Solventum™ Vitrebond™ Pulp Protect Liner/Base Used as a Liner/Base Under Dental Restorations

Start: Jan 2026Est. completion: Jun 2027160 patients
N/ANot Yet Recruiting
NCT02958891Jerusalem PharmaceuticalsData collection

Dental Health Epidemiology Among Israel Defense Forces (IDF) Recruits

Start: Mar 2016Est. completion: Dec 2017700 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,072 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.